PTPRC and renal cell carcinoma: Moreover, recent work in clinical renal cell carcinoma samples has shown stable expression of CD45, CD14, CD16, and CD56 on tumor cells in situ, strongly implicating trogocytosis as an active mechanism of membrane acquisition during tumor-immune cell contact in patients [35].